MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100312-PIP01-21-M01)

MHRA-100312-PIP01-21-M02

Scope of the Application

Active Substance(s)

RITLECITINIB TOSYLATE

Condition(s)

Treatment of alopecia areata

Pharmaceutical Form(s)

Capsule, hard Tablet

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Pfizer Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Pfizer Limited submitted to the licensing authority on 25/03/2024 13:47 GMT an application for a Modification

The procedure started on 27/03/2024 17:42 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100312-PIP01-21-M02

Of 05/07/2024 14:42 BST

On the adopted decision for RITLECITINIB TOSYLATE (MHRA-100312-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for RITLECITINIB TOSYLATE, Capsule, hard Tablet , ORAL USE .

This decision is addressed to Pfizer Limited, Ramsgate Road, Sandwich, UNITED KINGDOM, CT13 9NJ

ANNEX I

1. Waiver

1.1 Condition:

Treatment of alopecia areata The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age Pharmaceutical form(s): Capsule, hard Tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of alopecia areata (including alopecia universalis and alopecia totalis)

2.2 Indication(s) targeted by the PIP:

Treatment of severe alopecia areata

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Capsule, hard Tablet

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of hard capsules for children less than 12 years of age.
Non-Clinical Studies	1	Study 2 Definitive juvenile toxicity study in rats with a 2 month recovery period.
Clinical Studies	3	Study 3 (B7981031) Open label, non-randomised, multiple once daily dose, PK/PD study in children 6 years to less than 12 years of age with severe alopecia areata. Study 4 (B7981027) Randomised, double-blind, 24-week, placebo-controlled study to evaluate the safety and efficacy of ritlecitinib in children 6 years to less than 12 years of age with severe alopecia areata. Study 5 (B7981028) Long-term extension study to evaluate the long-term safety and long-term efficacy of ritlecitinib in participants with severe alopecia areata (AA) who successfully completed studies B7981031 or B7981027.
Extrapolation, Modeling & Simulation Studies	4	Study 6 Population PK analysis to characterise the PK of ritlecitinib in adult and adolescent AA participants and for dose-prediction in children 6 years to less than 12 years of age. Study 7 Population PK analysis to characterise the PK of ritlecitinib

		in adult and paediatric AA subjects and to evaluate overall dosing recommendation in the paediatric AA population. Study 8 Longitudinal exposure-response analysis of absolute SALT (severity of alopecia tool) score to characterise the temporal relationship of exposure-response of ritlecitinib on scalp hair growth in AA subjects. Study 9 Extrapolation study to support the extrapolation of efficacy, safety and clinical PK data of ritlecitinib to adolescents with severe AA.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/06/2024
Deferral of one or more studies contained in the paediatric investigation plan:	Yes